Abbvie Inc Common Stock (ABBV) 64.61 $ABBV AbbVie to

New Post Public Reply Private Reply Replies (0) Message Board

Sep 7, 2016 at 7:00 AM

Abbvie Inc Common Stock (ABBV) 64.61 $ABBV

AbbVie to Present at the Morgan Stanley Global Healthcare Conference
PR Newswire - Tue Aug 30, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 14, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 10:40 a.m. Central time.
ABBV: 64.61 (+0.49), MS: 31.75 (-0.14)

Zacks Value Investor Highlights: AbbVie, Berry Plastics, Hawaiian Holdings, Toll Brothers and Pulte
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 8:30AM CDT
Zacks Value Investor Highlights: AbbVie, Berry Plastics, Hawaiian Holdings, Toll Brothers and Pulte
BERY: 45.62 (-0.35), HA: 48.01 (+0.41), PHM: 20.84 (-0.04), ABBV: 64.61 (+0.49), TOL: 30.97 (+0.25)

How Value Investors Can Buy Growth
Tracey Ryniec - Zacks Investment Research - Wed Aug 17, 5:03PM CDT
Value and growth is a magical combination. Here???s how to get it.
BERY: 45.62 (-0.35), HA: 48.01 (+0.41), PHM: 20.84 (-0.04), ABBV: 64.61 (+0.49), TOL: 30.97 (+0.25)

J&J's (JNJ) Depression Treatment Esketamine Gets BTD
Arpita Dutt - Zacks Investment Research - Wed Aug 17, 5:50AM CDT
FDA granted Breakthrough Therapy Designation (BTD) to J&J's (JNJ) esketamine for major depressive disorder with imminent risk for suicide.
JNJ: 119.75 (+0.43), GERN: 3.02 (+0.27), ABBV: 64.61 (+0.49)

The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 8:30AM CDT
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
BIIB: 310.67 (-2.92), BMRN: 95.59 (-0.14), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49), REGN: 398.31 (+9.67)

Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
Arpita Dutt - Zacks Investment Research - Thu Aug 11, 4:30PM CDT
Earnings remained in focus with several companies including Regeneron (REGN) reporting second quarter results.
MDVN: 80.84 (-0.01), BIIB: 310.67 (-2.92), BMRN: 95.59 (-0.14), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49), MNTA: 12.23 (-0.07), REGN: 398.31 (+9.67)

Major Drug Makers Stocks Under Review -- Pfizer, AbbVie, Merck, and Johnson & Johnson
PR Newswire - Tue Aug 09, 8:17AM CDT
With the U.S. election fast approaching, some investors cannot help but question the outcome's probable impact on the Healthcare sector. A post-election scenario may lead to potential drug-price reductions and amended policies. This morning, Stock-Callers.com issued research reports on four major companies in the Drug Manufacturers industry, namely: Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Merck & Co. Inc. (NYSE: MRK), and Johnson & Johnson (NYSE: JNJ). Learn more about these stocks by downloading their free research reports in PDF format at:
JNJ: 119.75 (+0.43), MRK: 63.24 (+0.26), PFE: 34.77 (unch), ABBV: 64.61 (+0.49)

4 Biotech Stocks Poised to Surprise This Earnings Season
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 3:18PM CDT
Notwithstanding the sector declines, things appear far better now than they did a quarter ago for the biotech sector.
BIIB: 310.67 (-2.92), BMRN: 95.59 (-0.14), GILD: 77.88 (+0.99), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49), ARIA: 10.41 (+0.29), AEGN: 19.11 (+0.10)

Top Research Reports for Morgan Stanely, Union Pacific & AbbVie
Sheraz Mian - Zacks Investment Research - Mon Aug 01, 2:21PM CDT
Top Research Reports for Morgan Stanely, Union Pacific & AbbVie
KO: 43.79 (+0.13), MCK: 184.69 (+1.71), NWL: 54.04 (+0.47), ABBV: 64.61 (+0.49), APD: 157.40 (+0.31), UNP: 95.97 (+0.69), MS: 31.75 (-0.14)

Company News for August 01, 2016
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:10AM CDT
Companies in the News are: XRX,MRK,ABBV,EXPE
MRK: 63.24 (+0.26), EXPE: 113.91 (+1.86), ABBV: 64.61 (+0.49), XRX: 9.80 (-0.09)

What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 74.92 (+2.50), BIIB: 310.67 (-2.92), ABT: 42.16 (+0.07), JNJ: 119.75 (+0.43), GILD: 77.88 (+0.99), MRK: 63.24 (+0.26), PFE: 34.77 (unch), SGNT: 21.76 (+0.03), ABBV: 64.61 (+0.49), PRTA: 54.51 (+2.32), NVS: 80.15 (+0.77)

AbbVie (ABBV) Beats on 2Q Earnings, Revenues, Ups View
Arpita Dutt - Zacks Investment Research - Fri Jul 29, 9:44AM CDT
AbbVie (ABBV) raised its 2016 outlook following its Q2 earnings and revenue beat.
JNJ: 119.75 (+0.43), ABBV: 64.61 (+0.49), LLY: 78.51 (+1.66), BMY: 56.96 (+0.61)

Q2 GDP Disappoints, Q2 Earnings Mixed Ahead of Bell: XOM, CVX, UPS, ABBV, BCS
Mark Vickery - Zacks Investment Research - Fri Jul 29, 8:55AM CDT
Both GDP results and Exxon's (XOM) earnings for Q2 were below expectations. Who outperformed the consensus before the bell Friday?
BCS: 9.13 (-0.18), XOM: 88.57 (+1.15), ABBV: 64.61 (+0.49), CVX: 102.43 (+1.50), UPS: 109.50 (-0.09)

AbbVie (ABBV) Tops 2Q Earnings & Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 7:58AM CDT
AbbVie (ABBV) surpassed expectations in Q2 and raised its outlook for the year.
ABBV: 64.61 (+0.49)

AbbVie Reports Second-Quarter 2016 Financial Results
PR Newswire - Fri Jul 29, 6:38AM CDT
AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2016.
ABBV: 64.61 (+0.49)

AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
PR Newswire - Thu Jul 28, 4:30PM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the initiation of a Phase 3 clinical trial to study the safety and efficacy of venetoclax in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and have received one to three prior lines of therapy. The combination of venetoclax, bortezomib and dexamethasone will be compared to treatment with bortezomib, dexamethasone and placebo.1 Bortezomib, a proteasome inhibitor, and dexamethasone, a corticosteroid, are both common therapies used to treat symptomatic multiple myeloma.3
ABBV: 64.61 (+0.49)

The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
BIIB: 310.67 (-2.92), GILD: 77.88 (+0.99), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49), CELG: 106.71 (+1.22)

2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 5:47AM CDT
Two major large cap drug stocks, AbbVie (ABBV) and Merck (MRK) will be reporting second quarter results tomorrow.
BIIB: 310.67 (-2.92), JNJ: 119.75 (+0.43), GILD: 77.88 (+0.99), MRK: 63.24 (+0.26), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49)

Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 310.67 (-2.92), VRTX: 95.78 (+0.67), GILD: 77.88 (+0.99), ALXN: 125.85 (+2.18), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49), CELG: 106.71 (+1.22)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

El Pollo Loco Faces Class Action Over Wage Practices

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...